Greenwich LifeSciences (GLSI) Net Equity Issued and Repurchased (2021 - 2024)

Greenwich LifeSciences (GLSI) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $1.2 million in Q3 2024.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $1.2 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $2.3 million (changed N/A YoY) and the FY2021 annual result came in at $3.1 million, down 89.69% from the prior year.
• Net Equity Issued and Repurchased rose to $1.2 million in Q3 2024, from $266742.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $24.0 million in Q4 2020 to a low of $266742.0 in Q2 2024.
• A 3-year average of $4.8 million and a median of $872010.0 in 2021 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 97.65% in 2021, down 97.65% in 2021.
• Tracing GLSI's Net Equity Issued and Repurchased over 3 years: stood at $24.0 million in 2020, then plunged by 97.65% to $562596.0 in 2021, then surged by 110.0% to $1.2 million in 2024.
• The last three Net Equity Issued and Repurchased figures came in at $1.2 million (Q3 2024), $266742.0 (Q2 2024), and $299116.0 (Q1 2024), per Business Quant data.